Reata Pharma, Abbott commence BEACON Phase 3 trial
The trial is intended to evaluate the impact of bardoxolone methyl on time to important clinical outcomes. The companies expect to recruit around 16,00 patients in the trial
China-based IMPACT Therapeutics and Pharmanovia have entered an exclusive licensing deal worth up to €423.5m ($488.3m), giving Pharmanovia rights to manufacture, develop, and commercialise senaparib in 66 countries.
Boehringer obtains development and commercialisation rights to ZP2929 – Zealand Pharma’s glucagon/GLP-1 dual agonist drug candidate. Under the agreement, Zealand Pharma will be responsible for conducting the first